Evolution of conventional therapy in atopic dermatitis

Immunology and Allergy Clinics of North America

Volumn 30, Issue 3, 2010, Pages 351-368

  Wollenberg, Andreas ^a   Schnopp, Christina ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Atopic dermatitis; Calcineurin inhibitors; Emollients; Glucocorticosteroids; Therapy

Indexed keywords

2 PHENOXYETHANOL; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETAMETHASONE VALERATE; BUFEXAMAC; CALCINEURIN INHIBITOR; CEFALEXIN; CHLORHEXIDINE GLUCONATE; CORTICOSTEROID; CYCLOSPORIN; FLUTICASONE PROPIONATE; FUSIDIC ACID; GLUCOCORTICOID; GLYCEROL; HYPOCHLORITE SODIUM; METHYLPREDNISOLONE ACEPONATE; OCTENIDINE; PERMANGANATE POTASSIUM; PIMECROLIMUS; POLIDOCANOL; POVIDONE IODINE; PRIMROSE OIL; PSEUDOMONIC ACID; TACROLIMUS; TETRACYCLINE; TRICLOSAN; UREA; ZINC OXIDE;

ANTIBODY PRODUCTION; APPLICATION SITE BURNING; ATOPIC DERMATITIS; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BACTERIUM CULTURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; GENE MUTATION; HUMAN; IMMUNE RESPONSE; KAPOSI VARICELLIFORM ERUPTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN ATROPHY; STAPHYLOCOCCUS AUREUS; STRATUM CORNEUM;

ADRENAL CORTEX HORMONES; ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; DERMATITIS, ATOPIC; DRUG THERAPY; EMOLLIENTS; HUMANS; INFLAMMATION; SKIN;

EID: 77955479420     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2010.06.005     Document Type: Review

References (126)

1. Schmid M.H., Korting H.C. Coal tar, pine tar and sulfonated shale oil preparations: comparative activity, efficacy and safety. Dermatology 1996, 193(1):1-5.
2. Darsow U., Wollenberg A., Simon D., et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010, 24(3):317-328.
3. Schmid-Grendelmeier P., Simon D., Simon H.U., et al. Epidemiology, clinical features, and immunology of the " intrinsic" (non-IgE-mediated) type of atopic dermatitis (constitutional dermatitis). Allergy 2001, 56(9):841-849.
4. Bieber T. Atopic dermatitis. N Engl J Med 2008, 358(14):1483-1494.
5. Severity scoring of atopic dermatitis: the SCORAD Index. Dermatology 1993, 186:23-31. European Task Force on Atopic Dermatitis.
6. Elias P.M., Hatano Y., Williams M.L. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol 2008, 121(6):1337-1343.
7. Cork M.J., Danby S.G., Vasilopoulos Y., et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 2009, 129(8):1892-1908.
8. Scott I.R., Harding C.R., Barrett J.G. Histidine-rich protein of the keratohyalin granules. Source of the free amino acids, urocanic acid and pyrrolidone carboxylic acid in the stratum corneum. Biochim Biophys Acta 1982, 719(1):110-117.
9. Meyer W., Poehling H.M., Neurand K. Intraepidermal distribution of free amino acids in porcine skin. J Dermatol Sci 1991, 2(5):383-392.
10. Smith F.J., Irvine A.D., Terron-Kwiatkowski A., et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet 2006, 38(3):337-342.
11. Palmer C.N., Irvine A.D., Terron-Kwiatkowski A., et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006, 38(4):441-446.
12. Weidinger S., Illig T., Baurecht H., et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol 2006, 118(1):214-219.
13. Weidinger S., Rodriguez E., Stahl C., et al. Filaggrin mutations strongly predispose to early-onset and extrinsic atopic dermatitis. J Invest Dermatol 2007, 127(3):724-726.
14. Fallon P.G., Sasaki T., Sandilands A., et al. A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming. Nat Genet 2009, 41(5):602-608.
15. Sandilands A., Sutherland C., Irvine A.D., et al. Filaggrin in the frontline: role in skin barrier function and disease. J Cell Sci 2009, 122(Pt 9):1285-1294.
16. Williams H.C. Evening primrose oil for atopic dermatitis. BMJ 2003, 327(7428):1358-1359.
17. Sator P.G., Schmidt J.B., Honigsmann H. Comparison of epidermal hydration and skin surface lipids in healthy individuals and in patients with atopic dermatitis. J Am Acad Dermatol 2003, 48(3):352-358.
18. Bleck O., Abeck D., Ring J., et al. Two ceramide subfractions detectable in Cer(AS) position by HPTLC in skin surface lipids of non-lesional skin of atopic eczema. J Invest Dermatol 1999, 113(6):894-900.
19. Hara J., Higuchi K., Okamoto R., et al. High-expression of sphingomyelin deacylase is an important determinant of ceramide deficiency leading to barrier disruption in atopic dermatitis. J Invest Dermatol 2000, 115(3):406-413.
20. Higuchi K., Hara J., Okamoto R., et al. The skin of atopic dermatitis patients contains a novel enzyme, glucosylceramide sphingomyelin deacylase, which cleaves the N-acyl linkage of sphingomyelin and glucosylceramide. Biochem J 2000, 350(Pt 3):747-756.
21. Wollenberg A., Wetzel S., Burgdorf W.H.C., et al. Viral infections in atopic dermatitis: pathogenic aspects and clinical management. J Allergy Clin Immunol 2003, 112:667-674.
22. Wollenberg A., Zoch C., Wetzel S., et al. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. J Am Acad Dermatol 2003, 49(2):198-205.
23. Mempel M., Lina G., Hojka M., et al. High prevalence of superantigens associated with the egc locus in Staphylococcus aureus isolates from patients with atopic eczema. Eur J Clin Microbiol Infect Dis 2003, 22(5):306-309.
24. Wollenberg A., Klein E. Current aspects of innate and adaptive immunity in atopic dermatitis. Clin Rev Allergy Immunol 2007, 33(1-2):35-44.
25. Ong P.Y., Ohtake T., Brandt C., et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002, 347(15):1151-1160.
26. Schauber J., Gallo R.L. Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol 2008, 122(2):261-266.
27. Cho S.H., Strickland I., Tomkinson A., et al. Preferential binding of Staphylococcus aureus to skin sites of Th2-mediated inflammation in a murine model. J Invest Dermatol 2001, 116(5):658-663.
28. Mempel M., Schmidt T., Weidinger S., et al. Role of Staphylococcus aureus surface-associated proteins in the attachment to cultured HaCaT keratinocytes in a new adhesion assay. J Invest Dermatol 1998, 111(3):452-456.
29. Kisich K.O., Carspecken C.W., Fieve S., et al. Defective killing of Staphylococcus aureus in atopic dermatitis is associated with reduced mobilization of human beta-defensin-3. J Allergy Clin Immunol 2008, 122(1):62-68.
30. Mrabet-Dahbi S., Dalpke A.H., Niebuhr M., et al. The Toll-like receptor 2 R753Q mutation modifies cytokine production and Toll-like receptor expression in atopic dermatitis. J Allergy Clin Immunol 2008, 121(4):1013-1019.
31. Bunikowski R., Mielke M.E., Skarabis H., et al. Evidence for a disease-promoting effect of Staphylococcus aureus-derived exotoxins in atopic dermatitis. J Allergy Clin Immunol 2000, 105(4):814-819.
32. Schnopp C., Grosch J., Ring J., et al. Microbial allergen-specific IgE is not suitable to identify the intrinsic form of atopic eczema in children. J Allergy Clin Immunol 2008, 121(1):267-268. e261 [author reply: 268].
33. Mihm M.C., Soter N.A., Dvorak H.F., et al. The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol 1976, 67:305-312.
34. Hanifin J.M., Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980, 92:44-47.
35. Wollenberg A., Kraft S., Hanau D., et al. Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J Invest Dermatol 1996, 106(3):446-453.
36. Maurer D., Fiebiger E., Ebner C., et al. Peripheral blood dendritic cells express FceRI as a complex composed of FceRIa and FceRIg-Chains and can use this Receptor for IgE-mediated Allergen presentation. J Immunol 1996, 157:607-616.
37. Sonkoly E., Muller A., Lauerma A.I., et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006, 117(2):411-417.
38. Wollenberg A., Bieber T. Proactive therapy of atopic dermatitis-an emerging concept. Allergy 2009, 64:276-278.
39. Wollenberg A., Frank R., Kroth J., et al. Proactive therapy of atopic eczema-an evidence-based concept with a behavioral background. J Dtsch Dermatol Ges 2009, 7:117-121.
40. Buraczewska I., Berne B., Lindberg M., et al. Changes in skin barrier function following long-term treatment with moisturizers, a randomized controlled trial. Br J Dermatol 2007, 156(3):492-498.
41. Wohlrab J. Adjuvante Therapie der atopischen. Dermatitis 2005, Vol. 5.
42. Gehring W. Basic therapy in atopic eczema. Handbook or atopic eczema 2005, 453-467. Springer, Berlin. 2nd edition. J. Ring, B. Przybilla, T. Ruzicka (Eds.).
43. Akdis C.A., Akdis M., Bieber T., et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 2006, 61(8):969-987.
44. Elias P.M. An appropriate response to the black-box warning: corrective, barrier repair therapy in atopic dermatitis. Clin Med Dermatol 2009, 2:1-3.
45. Szczepanowska J., Reich A., Szepietowski J.C. Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: a randomized comparative study. Pediatr Allergy Immunol 2008, 19(7):614-618.
46. Cork M.J., Britton J., Butler L., et al. Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. Br J Dermatol 2003, 149(3):582-589.
47. Eberlein B., Eicke C., Reinhardt H.W., et al. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol 2008, 22(1):73-82.
48. Sugarman J.L., Parish L.C. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. J Drugs Dermatol 2009, 8(12):1106-1111.
49. Jensen J.M., Pfeiffer S., Witt M., et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol 2009, 124(3 Suppl 2):R19-R28.
50. Kao J.S., Fluhr J.W., Man M.Q., et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 2003, 120(3):456-464.
51. Leyden J.J., Marples R.R., Kligman A.M. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol 1974, 90(5):525-530.
52. Aly R., Maibach H.I., Shinefield H.R. Microbial flora of atopic dermatitis. Arch Dermatol 1977, 113(6):780-782.
53. Breuer K., Haussler S., Kapp A., et al. Staphylococcus aureus: colonizing features and influence of an antibacterial treatment in adults with atopic dermatitis. Br J Dermatol 2002, 147(1):55-61.
54. Hoeger P.H., Lenz W., Boutonnier A., et al. Staphylococcal skin colonization in children with atopic dermatitis: prevalence, persistence, and transmission of toxigenic and nontoxigenic strains. J Infect Dis 1992, 165(6):1064-1068.
55. Ewing C.I., Ashcroft C., Gibbs A.C., et al. Flucloxacillin in the treatment of atopic dermatitis. Br J Dermatol 1998, 138(6):1022-1029.
56. Hayakawa K., Hirahara K., Fukuda T., et al. Risk factors for severe impetiginized atopic dermatitis in Japan and assessment of its microbiological features. Clin Exp Dermatol 2009, 34(5):e63-e65.
57. Stalder J.F., Fleury M., Sourisse M., et al. Local steroid therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol 1994, 131(4):536-540.
58. Remitz A., Kyllonen H., Granlund H., et al. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol 2001, 107:196-197.
59. Boguniewicz M., Leung D.Y. Pathophysiologic mechanisms in atopic dermatitis. Semin Cutan Med Surg 2001, 20(4):217-225.
60. Birnie A.J., Bath-Hextall F.J., Ravenscroft J.C., et al. Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Cochrane Database Syst Rev 2008, (3). CD003871.
61. Lever R., Hadley K., Downey D., et al. Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol 1988, 119(2):189-198.
62. Gong J.Q., Lin L., Lin T., et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol 2006, 155(4):680-687.
63. Schuttelaar M.L., Coenraads P.J. A randomized, double-blind study to assess the efficacy of addition of tetracycline to triamcinolone acetonide in the treatment of moderate to severe atopic dermatitis. J Eur Acad Dermatol Venereol 2008, 22(9):1076-1082.
64. Yang L.P., Keam S.J. Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections. Drugs 2008, 68(6):855-873.
65. Gloor M., Becker A., Wasik B., et al. Hautarzt 2002, 53(11):724-729. [in German].
66. Ledder R.G., Gilbert P., Willis C., et al. Effects of chronic triclosan exposure upon the antimicrobial susceptibility of 40 ex-situ environmental and human isolates. J Appl Microbiol 2006, 100(5):1132-1140.
67. Moss T., Howes D., Williams F.M. Percutaneous penetration and dermal metabolism of triclosan (2,4, 4'-trichloro-2'-hydroxydiphenyl ether). Food Chem Toxicol 2000, 38(4):361-370.
68. Allmyr M., Adolfsson-Erici M., McLachlan M.S., et al. Triclosan in plasma and milk from Swedish nursing mothers and their exposure via personal care products. Sci Total Environ 2006, 372(1):87-93.
69. Dayan A.D. Risk assessment of triclosan [Irgasan] in human breast milk. Food Chem Toxicol 2007, 45(1):125-129.
70. Tan W.P., Suresh S., Tey H.L., et al. A randomized double-blind controlled trial to compare a triclosan-containing emollient with vehicle for the treatment of atopic dermatitis. Clin Exp Dermatol 2010, 35(4):e109-e112.
71. Stalder J.F., Fleury M., Sourisse M., et al. Comparative effects of two topical antiseptics (chlorhexidine vs KMn04) on bacterial skin flora in atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1992, 176:132-134.
72. Jee R., Nel L., Gnanakumaran G., et al. Four cases of anaphylaxis to chlorhexidine impregnated central venous catheters: a case cluster or the tip of the iceberg?. Br J Anaesth 2009, 103(4):614-615.
73. Nagendran V., Wicking J., Ekbote A., et al. IgE-mediated chlorhexidine allergy: a new occupational hazard?. Occup Med (Lond) 2009, 59(4):270-272.
74. Garvey L.H., Kroigaard M., Poulsen L.K., et al. IgE-mediated allergy to chlorhexidine. J Allergy Clin Immunol 2007, 120(2):409-415.
75. Huang J.T., Abrams M., Tlougan B., et al. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics 2009, 123(5):e808-e814.
76. Sugimoto K., Ishikawa N., Terano T., et al. The importance of bacterial superantigens produced by Staphylococcus aureus in the treatment of atopic dermatitis using povidone-iodine. Dermatology 2006, 212(Suppl 1):26-34.
77. Sugimoto K., Kuroki H., Kanazawa M., et al. New successful treatment with disinfectant for atopic dermatitis. Dermatology 1997, 195(Suppl 2):62-68.
78. Akiyama H., Tada J., Toi J., et al. Changes in Staphylococcus aureus density and lesion severity after topical application of povidone-iodine in cases of atopic dermatitis. J Dermatol Sci 1997, 16(1):23-30.
79. Gauger A., Fischer S., Mempel M., et al. Efficacy and functionality of silver-coated textiles in patients with atopic eczema. J Eur Acad Dermatol Venereol 2006, 20(5):534-541.
80. Koller D.Y., Halmerbauer G., Bock A., et al. Action of a silk fabric treated with AEGIS in children with atopic dermatitis: a 3-month trial. Pediatr Allergy Immunol 2007, 18(4):335-338.
81. Stinco G., Piccirillo F., Valent F. A randomized double-blind study to investigate the clinical efficacy of adding a non-migrating antimicrobial to a special silk fabric in the treatment of atopic dermatitis. Dermatology 2008, 217(3):191-195.
82. Darsow U., Lubbe J., Taieb A., et al. Position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2005, 19(3):286-295.
83. Walsh P., Aeling J.L., Huff L., et al. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol 1993, 29(3):501-503.
84. Charman C., Williams H. The use of corticosteroids and corticosteroid phobia in atopic dermatitis. Clin Dermatol 2003, 21(3):193-200.
85. Zuberbier T., Orlow S.J., Paller A.S., et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006, 118(1):226-232.
86. Bornhövd E., Burgdorf W.H.C., Wollenberg A. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol 2001, 45:736-743.
87. Ruzicka T., Bieber T., Schöpf E., et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997, 337:816-821.
88. Van Leent E.J., Graber M., Thurston M., et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998, 134(7):805-809.
89. Reitamo S., Rustin M., Ruzicka T., et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002, 109:547-555.
90. Luger T., Van-Leent E.J., Graeber M., et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001, 144(4):788-794.
91. Ring J., Barker J., Behrendt H., et al. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. J Eur Acad Dermatol Venereol 2005, 19(6):663-671.
92. Wollenberg A., Reitamo S., Girolomoni G., et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008, 63(7):742-750.
93. Lübbe J., Pournaras C.C., Saurat J.H. Eczema herpeticum during treatment of atopic dermatitis with 0.1% tacrolimus ointment. Dermatology 2000, 201(3):249-251.
94. Wetzel S., Wollenberg A. Eczema molluscatum in tacrolimus treated atopic dermatitis. Eur J Dermatol 2004, 14(1):73-74.
95. Reitamo S., Rissanen J., Remitz A., et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998, 111:396-398.
96. Queille-Roussel C., Paul C., Duteil L., et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001, 144:507-513.
97. Arellano F.M., Wentworth C.E., Arana A., et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007, 127(4):808-816.
98. Margolis D.J., Hoffstad O., Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007, 214(4):289-295.
99. Reitamo S., Wollenberg A., Schopf E., et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000, 136(8):999-1006.
100. Thaci D., Reitamo S., Gonzalez Ensenat M.A., et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol 2008, 159(6):1348-1356.
101. Hoeger P.H., Lee K.H., Jautova J., et al. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial. Br J Dermatol 2009, 160(2):415-422.
102. Wollenberg A., Reitamo S., Atzori F., et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008, 63(6):742-750.
103. Proksch E., Folster-Holst R., Jensen J.M. Skin barrier function, epidermal proliferation and differentiation in eczema. J Dermatol Sci 2006, 43(3):159-169.
104. Kerschenlohr K., Darsow U., Burgdorf W.H., et al. Lessons from atopy patch testing in atopic dermatitis. Curr Allergy Asthma Rep 2004, 4(4):285-289.
105. Darsow U., Laifaoui J., Kerschenlohr K., et al. The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: a European multicenter study. Allergy 2004, 59(12):1318-1325.
106. Macheleidt O., Kaiser H.W., Sandhoff K. Deficiency of epidermal protein-bound omega-hydroxyceramides in atopic dermatitis. J Invest Dermatol 2002, 119(1):166-173.
107. Howell M.D., Kim B.E., Gao P., et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2007, 120(1):150-155.
108. Bieber T., Braun-Falco O. IgE-bearing Langerhans cells are not specific to atopic eczema but are found in inflammatory skin diseases. J Am Acad Dermatol 1991, 24(4):658-659.
109. Bieber T., de la Salle H., Wollenberg A., et al. Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon RI). J Exp Med 1992, 175(5):1285-1290.
110. Wang B., Rieger A., Kilgus O., et al. Epidermal Langerhans cells from normal human skin bind monomeric IgE via FceRI. J Exp Med 1992, 175:1353-1365.
111. Semper A.E., Heron K., Woollard A.C., et al. Surface expression of Fc epsilon RI on Langerhans' cells of clinically uninvolved skin is associated with disease activity in atopic dermatitis, allergic asthma, and rhinitis. J Allergy Clin Immunol 2003, 112(2):411-419.
112. Wollenberg A., Wen S., Bieber T. Phenotyping of epidermal dendritic cells: clinical applications of a flow cytometric micromethod. Cytometry 1999, 37:147-155.
113. Wollenberg A., Sidhu M.K., Odeyemi I., et al. Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2008, 159(6):1322-1330.
114. Breneman D., Fleischer A.B., Abramovits W., et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol 2008, 58(6):990-999.
115. Hanifin J., Gupta A.K., Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002, 147(3):528-537.
116. Berth-Jones J., Damstra R.J., Golsch S., et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003, 326(7403):1367-1372.
117. Peserico A., Stadtler G., Sebastian M., et al. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol 2008, 158(4):801-807.
118. Heine G., Schnuch A., Uter W., et al. Type-IV sensitization profile of individuals with atopic eczema: results from the Information Network of Departments of Dermatology (IVDK) and the German Contact Dermatitis Research Group (DKG). Allergy 2006, 61(5):611-616.
119. Heine G., Schnuch A., Uter W., et al. Frequency of contact allergy in German children and adolescents patch tested between 1995 and 2002: results from the Information Network of Departments of Dermatology and the German Contact Dermatitis Research Group. Contact Derm 2004, 51(3):111-117.
120. Schempp C.M., Hezel S., Simon J.C. Hautarzt Mar 2003, 54(3):248-253. [in German].
121. Hoare C., Li Wan Po A., Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000, 4(37):1-191.
122. Hagvall L., Skold M., Brared-Christensson J., et al. Lavender oil lacks natural protection against autoxidation, forming strong contact allergens on air exposure. Contact Derm 2008, 59(3):143-150.
123. Adisen E., Onder M. Allergic contact dermatitis from Laurus nobilis oil induced by massage. Contact Derm 2007, 56(6):360-361.
124. Rutherford T., Nixon R., Tam M., et al. Allergy to tea tree oil: retrospective review of 41 cases with positive patch tests over 4.5 years. Australas J Dermatol 2007, 48(2):83-87.
125. Corazza M., Lauriola M.M., Poli F., et al. Contact vulvitis due to Pseudowintera Colorata in a topical herbal medicament. Acta Derm Venereol 2007, 87(2):178-179.
126. Simpson E.L., Law S.V., Storrs F.J. Prevalence of botanical extract allergy in patients with contact dermatitis. Dermatitis 2004, 15(2):67-72.